TY - JOUR
T1 - Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction
AU - Gochi, Tomoko
AU - Umeda, Hisashi
AU - Yoshida, Naoki
AU - Maekawa, Hironobu
AU - Watanabe, Kosuke
AU - Okada, Taro
AU - Katoh, Toshiaki
AU - Asai, Toru
AU - Tani, Tomomitsu
AU - Yokoya, Masaki
AU - Murakami, Yoshimasa
AU - Matsushita, Toyoaki
AU - Shimizu, Takeshi
AU - Ozaki, Yukio
AU - Hiramitsu, Shinya
AU - Murohara, Toyoaki
AU - Nomura, Masanori
AU - Morimoto, Shinichiro
AU - Hishida, Hitoshi
PY - 2006
Y1 - 2006
N2 - Objectives. This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction. Methods. A series of 100 consecutive patients (September 2004 to November 2005) with acute myocardial infarction undergoing primary stenting using SES(≤ 24 hr)was compared with 100 consecutive patients (September 2003 to August 2004) treated with bare metal stent (BMS). The frequency of major adverse cardiac events (MACE) and stent thrombosis, and status of ticlopidine administration were assessed at 270 days. Results. The rates of premature discontinuation of ticlopidine (SES group < 3 months: 11%, BMS group < 1 month: 11%, p = NS)and stent thrombosis (SES group: 1%, BMS group: 0%, p = NS)were similar in the two groups. At follow-up, restenosis rate and target vessel revascularization rate were lower in the SES group(4% vs 19%, p< 0.001 and 4% vs 10%, p = 0.149, respectively). Furthermore, the occurrence of MACE at 270 days was significantly less frequent in the SES group compared with the BMS.
AB - Objectives. This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction. Methods. A series of 100 consecutive patients (September 2004 to November 2005) with acute myocardial infarction undergoing primary stenting using SES(≤ 24 hr)was compared with 100 consecutive patients (September 2003 to August 2004) treated with bare metal stent (BMS). The frequency of major adverse cardiac events (MACE) and stent thrombosis, and status of ticlopidine administration were assessed at 270 days. Results. The rates of premature discontinuation of ticlopidine (SES group < 3 months: 11%, BMS group < 1 month: 11%, p = NS)and stent thrombosis (SES group: 1%, BMS group: 0%, p = NS)were similar in the two groups. At follow-up, restenosis rate and target vessel revascularization rate were lower in the SES group(4% vs 19%, p< 0.001 and 4% vs 10%, p = 0.149, respectively). Furthermore, the occurrence of MACE at 270 days was significantly less frequent in the SES group compared with the BMS.
UR - http://www.scopus.com/inward/record.url?scp=34347328712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347328712&partnerID=8YFLogxK
M3 - Article
C2 - 17136820
AN - SCOPUS:34347328712
SN - 0914-5087
VL - 48
SP - 253
EP - 261
JO - Journal of cardiology
JF - Journal of cardiology
IS - 5
ER -